Vertex Pharmaceuticals Inc- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 Vertex Pharmaceuticals Inc 公司

Vertex Pharmaceuticals Incorporated 是一家全球性生物技術公司。該公司專注於投資科學創新，爲患有嚴重疾病的人創造變革性藥物，重點關注專業市場。該公司擁有四種獲批的治療囊性纖維化 (CF) 潛在病因的藥物，以及一種獲批的治療嚴重鐮狀細胞病 (SCD) 和輸血依賴性β地中海貧血 (TDT) 的療法。其產品線包括 CF、SCD、TDT、急性和神經性疼痛、APOL1 介導的腎臟疾病、1 型糖尿病、1 型肌強直性營養不良和 α-1 抗胰蛋白酶缺乏症的臨牀階段項目。其上市藥物包括 TRIKAFTA/KAFTRIO、SYMDEKO/SYMKEVI（tezacaftor/ivacaftor 和 ivacaftor）、ORKAMBI（lumacaftor/ivacaftor）和 KALYDECO（ivacaftor）。該公司正在開發非自體（同種異體）完全分化、幹細胞衍生的胰島細胞療法，旨在取代 1 型糖尿病患者體內被破壞的產生胰島素的胰島細胞。

公司簡介

公司代碼VRTX

公司名稱Vertex Pharmaceuticals Inc

上市日期Jul 24, 1991

成立日期1989

CEODr. Reshma Kewalramani

員工數量6100

證券類型Ordinary Share

年結日Jul 24

公司地址50 Northern Avenue

城市BOSTON

上市交易所NASDAQ Global Select Consolidated

國家United States of America

郵編02210

電話16173416393

網址https://www.vrtx.com/

公司代碼VRTX

上市日期Jul 24, 1991

成立日期1989

公司高階主管

名稱

名稱/職務

職務

持股

持股變動

Dr. Reshma Kewalramani

President, Chief Executive Officer, Director

41.81K

+38.72%

Mr. Bruce I. Sachs

Lead Independent Director

40.00K

--

Dr. Carmen Bozic, M.D.

Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer

32.67K

+40.46%

Dr. Ourania (Nia) Tatsis, Ph.D.

Executive Vice President, Chief Regulatory and Quality Officer

30.30K

+19.95%

Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.

Executive Chairman of the Board

24.47K

--

Mr. Stuart A. Arbuckle

Chief Operating Officer, Executive Vice President

23.68K

+38.42%

Mr. Jonathan Biller, J.D.

Executive Vice President, Chief Legal Officer

17.61K

+5.74%

Ms. Diana L. Mckenzie

Independent Director

8.63K

+485.29%

Mr. Lloyd A. Carney

Independent Director

6.32K

--

Dr. Sangeeta N. Bhatia, M.D., Ph.D.

Independent Director

4.43K

--

名稱

名稱/職務

職務

持股

持股變動

Dr. Reshma Kewalramani

President, Chief Executive Officer, Director

41.81K

+38.72%

Mr. Bruce I. Sachs

Lead Independent Director

40.00K

--

Dr. Carmen Bozic, M.D.

Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer

32.67K

+40.46%

Dr. Ourania (Nia) Tatsis, Ph.D.

Executive Vice President, Chief Regulatory and Quality Officer

30.30K

+19.95%

Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.

Executive Chairman of the Board

24.47K

--

Mr. Stuart A. Arbuckle

Chief Operating Officer, Executive Vice President

23.68K

+38.42%

收入明細

單位: USD更新時間: 4月6日週日

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

業務USD

名稱

營收

佔比

TRIKAFTA

10.24B

92.91%

Other CF products

781.50M

7.09%

地區USD

名稱

營收

佔比

United States

6.68B

60.66%

Europe

3.45B

31.34%

Other

881.30M

8.00%

業務

地區

業務USD

名稱

營收

佔比

TRIKAFTA

10.24B

92.91%

Other CF products

781.50M

7.09%

股東統計

更新時間: 2月21日週五

持股股東

股東類型

持股股東

股東統計

佔比

Capital World Investors

11.02%

The Vanguard Group, Inc.

9.00%

BlackRock Institutional Trust Company, N.A.

5.57%

State Street Global Advisors (US)

4.66%

Capital Research Global Investors

4.06%

Other

65.69%

持股股東

股東統計

佔比

Capital World Investors

11.02%

The Vanguard Group, Inc.

9.00%

BlackRock Institutional Trust Company, N.A.

5.57%

State Street Global Advisors (US)

4.66%

Capital Research Global Investors

4.06%

Other

65.69%

股東類型

股東統計

佔比

Investment Advisor

48.53%

Investment Advisor/Hedge Fund

37.68%

Pension Fund

2.67%

Research Firm

2.18%

Bank and Trust

1.87%

Sovereign Wealth Fund

1.44%

Hedge Fund

1.43%

Individual Investor

0.13%

Foundation

0.11%

Other

3.96%

機構持股

更新時間: 1月19日週日

報告期間

機構數

持股數

持股佔比

持股變動

2025Q1

2830

248.86M

96.80%

-1.60M

2024Q4

2877

248.76M

96.87%

-2.25M

2024Q3

2786

247.87M

96.18%

-4.19M

2024Q2

2747

248.36M

96.27%

-4.14M

2024Q1

2680

247.63M

95.87%

-4.48M

2023Q4

2608

247.92M

96.20%

-4.51M

2023Q3

2477

248.64M

96.45%

-6.19M

2023Q2

2488

248.89M

96.55%

-7.11M

2023Q1

2468

250.11M

97.13%

-4.74M

2022Q4

2454

248.59M

96.73%

-7.80M

股東持股明細

名稱

持股數

佔比

持股變動

變動比例

公告日期

Capital World Investors

28.33M

11.02%

+1.51M

+5.65%

Dec 31, 2024

The Vanguard Group, Inc.

23.15M

9%

+102.48K

+0.44%

Dec 31, 2024

BlackRock Institutional Trust Company, N.A.

14.33M

5.57%

-90.57K

-0.63%

Dec 31, 2024

State Street Global Advisors (US)

11.98M

4.66%

+163.16K

+1.38%

Dec 31, 2024

Capital Research Global Investors

10.43M

4.06%

+1.43M

+15.85%

Dec 31, 2024

Fidelity Management & Research Company LLC

9.11M

3.54%

-1.25M

-12.07%

Dec 31, 2024

Wellington Management Company, LLP

5.92M

2.3%

+1.12M

+23.28%

Dec 31, 2024

Geode Capital Management, L.L.C.

5.65M

2.2%

-287.65K

-4.85%

Dec 31, 2024

Invesco Capital Management (QQQ Trust)

5.33M

2.07%

+71.48K

+1.36%

Feb 28, 2025

JP Morgan Asset Management

4.62M

1.8%

-403.93K

-8.04%

Dec 31, 2024

持股ETF

更新時間: 4月6日週日

機構名稱

佔比

VanEck Biotech ETF

10.56%

Tema Neuroscience and Mental Health ETF

9.89%

Invesco Nasdaq Biotechnology ETF

8.48%

ProShares Ultra Nasdaq Biotechnology

8.08%

iShares Biotechnology ETF

7.22%

Indexperts Gorilla Aggressive Growth ETF

6.23%

Natixis Loomis Sayles Focused Growth ETF

4.96%

Franklin Genomic Advancements ETF

4.66%

Amplify AI Powered Equity ETF

4.21%

First Trust NYSE Arca Biotechnology Index Fund

3.65%

VanEck Biotech ETF

佔比10.56%

Tema Neuroscience and Mental Health ETF

佔比9.89%

Invesco Nasdaq Biotechnology ETF

佔比8.48%

ProShares Ultra Nasdaq Biotechnology

佔比8.08%

iShares Biotechnology ETF

佔比7.22%

Indexperts Gorilla Aggressive Growth ETF

佔比6.23%

Natixis Loomis Sayles Focused Growth ETF

佔比4.96%

Franklin Genomic Advancements ETF

佔比4.66%

Amplify AI Powered Equity ETF

佔比4.21%

First Trust NYSE Arca Biotechnology Index Fund

佔比3.65%

分紅派息

近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股

公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

Vertex Pharmaceuticals Inc

489.100USD

Vertex Pharmaceuticals Inc

489.100

概覽

公司